Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ACHILLES THERAPEUTICS PLC

(ACHL)
  Rapport
Vertraagde tijd Nasdaq  -  17:21 30-11-2022
1.980 USD   +4.21%
22/11Sectorupdate: Gezondheidszorgaandelen dinsdagmiddag hoger
MT
22/11Sectorupdate: Gezondheidszorgaandelen stijgen mee met bredere markten
MT
22/11Achilles Therapeutics krijgt Amerikaans octrooi voor immunotherapie gericht op klonale Neoantigenen die zijn geïdentificeerd met behulp van een eigen methode.
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Dagen
:
Uren
:
Minuten
:
Seconden
Nieuws in andere talen op ACHILLES THERAPEUTICS PLC
22/11Sector Update: Health Care Stocks Carried Higher Tuesday Afternoon
22/11Sector Update: Health Care Stocks Carried Higher with Broader Markets
22/11Achilles Therapeutics Granted US Patent on Immunotherapy Targeting Clonal Neoantigens I..
22/11Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal ..
08/11Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Month..
08/11Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business ..
21/10European ADRs Move Higher in Friday Trading
06/10Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Rou..
23/09European ADRs Fall in Friday Trading
09/08Achilles Therapeutics : Reports Second Quarter 2022 Financial Results and Recent Business ..
09/08Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business..
09/08Achilles Therapeutics plc Reports Earnings Results for the Second Quarter and Six Month..
25/07Achilles Therapeutics : Cell Therapy Potency Assay Summit
21/07Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized ..
30/06Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, ..
30/06Achilles Therapeutics plc Announces Management Appointments, Effective July 1, 2022
28/06Achilles Therapeutics : Results of Annual General Meeting - Form 6-K
21/06Achilles Therapeutics Recognized with the 2022 PING Innovation Award
26/05Achilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION -..
17/05European ADRs Move Higher in Tuesday Trading
10/05Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business ..
10/05Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31..
09/05Achilles Therapeutics Doses First Patient With Higher-Dose Clonal Neoantigen-Reactive T..
09/05Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON T..
09/05Achilles Therapeutics plc Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIR..
04/05European ADRs Decline in Wednesday Trading
04/05Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
04/05Achilles Therapeutics plc Announces Management Changes
03/05Achilles Therapeutics to Present at Upcoming Conferences
14/04Transcript : Achilles Therapeutics plc - Special Call
12/04Achilles Therapeutics Signs T-Cell Therapy Deal With Center for Breakthrough Medicines;..
12/04The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therap..
12/04Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for M..
12/04Achilles Therapeutics plc Announces Manufacturing Expansion in the UK and Partnership f..
12/04The Center for Breakthrough Medicines Strikes Multi-Year Deal with Achilles Therapeutic..
06/04European ADRs Advance in Wednesday Trading
05/04Achilles Therapeutics to Present at Upcoming Conferences
04/04Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from..
08/03Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
01/03Achilles Therapeutics Selects Netrality's 401 North Broad for United States Headquarter..
01/03Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Re..
01/03Achilles Therapeutics plc Reports Earnings Results for the Full Year Ended December 31,..
01/03Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended Decembe..
28/02European ADRs Move Lower in Monday Trading
07/02Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena G..
07/02Achilles Therapeutics plc Appoints Alena Gros and Ben Creelan to Its Scientific Advisor..
13/01Achilles Therapeutics Provides Business Update and Outlook for 2022
10/01Achilles Therapeutics : Corporate Presentation - January 2022
2021European ADRs Move Higher in Thursday Trading
2021European ADRs Rising Wednesday
2021Achilles Therapeutics to present at the†40th Annual J.P. Morgan Healthcare Conference
2021Achilles Therapeutics plc(NasdaqGS:ACHL) added to NAS..
2021Esmo Io 2021 Poster 58p : Achilles VELOS Process 2 generates a >10-fold improvement in cNe..
2021European ADRs Move Lower in Friday Trading
2021Achilles Post-SITC Review and Corporate Update
2021Sitc 2021 Poster 193 : The Achilles VELOSTM Process 2 boosts the dose of highly functional..
2021Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer Annual M..
2021Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business ..
2021Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business ..
2021Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Month..
2021Sitc 2021 Poster 543 : Sensitive quantification and tracking of the active components of c..
2021European ADRs Gain Thursday as Anheuser-Busch InBev Jumps 10%
2021European ADRs 0.3% Lower Wednesday as Equinor, Rio Tinto Retreat
2021European ADRs Move Lower in Monday Trading
2021Achilles Therapeutics : Presents Research Data for Velos Cancer Th..
2021Esgct 2021 Or54 : Multicentre, prospective research protocol for development of a clonal n..
2021Achilles Therapeutics : Presents Data at the 2021 European Society for Gene and Cell Thera..
2021Achilles Therapeutics Presents Data At the 2021 European Society for Gene and Cell Ther..
2021Achilles Therapeutics : to join the Northern Alliance Advanced Therapy Treatment Centre co..
2021Achilles Therapeutics plc to join the Northern Alliance Advanced Therapy Treatment Cent..
2021Achilles Therapeutics : to Present at Upcoming Scientific Congresses
2021Certain Deferred Shares of Achilles Therapeutics plc are subject to a Lock-Up Agreement..
2021Certain Ordinary Shares of Achilles Therapeutics plc are subject to a Lock-Up Agreement..
2021Certain Options of Achilles Therapeutics plc are subject to a Lock-Up Agreement Ending ..
2021Achilles Therapeutics : to Present at Upcoming Investor Conferences
2021Achilles Therapeutics : Issued US, European Patents
2021Achilles Therapeutics : Announces Grant of US and European Patents
2021Achilles Therapeutics : Q2 Loss Shrinks, Shares Jump
2021Achilles Therapeutics : Reports Second Quarter 2021 Financial Results and Recent Business ..
2021Achilles Therapeutics : Reports Second Quarter 2021 Financial Results and Recent Business ..
2021Achilles Therapeutics plc Announces Unaudited Consolidated Earnings Results for the Sec..
2021Achilles Therapeutics : Enrolls First US Patient in Phase 1/2a Stu..
2021Achilles Therapeutics : Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced ..
2021Achilles Therapeutics Enrolls First Us Patient in Ongoing Phase I/Iia Study in Advanced..
2021Achilles Therapeutics : Results of Annual General Meeting (Form 6-K)
2021Achilles Therapeutics : Presents Phase I/IIa Clinical Trial Design..
2021Achilles Therapeutics : Details Phase I/IIa Clinical Trial Design of CHIRON in Patients wi..
2021Achilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION (..
2021Achilles Therapeutics : Reported first clinical data from the CHIRON and THETIS trials and..
2021Achilles Therapeutics : Reports Wider Q1 Loss
2021Achilles Therapeutics plc Reports Unaudited Consolidated Earnings Results for the First..
2021Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business ..
2021Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium
2021Achilles Therapeutics to present at the†BofA Securities 2021 Virtual Healthcare Confere..
2021Achilles Therapeutics : Appoints Julie O'Neill to Board of Directors and Markwin Velders, ..
2021Achilles Therapeutics Appoints Julie O'Neill to Board of Directors and Markwin Velders,..
2021Achilles Therapeutics plc Announces Changes to Its Board
2021Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Trac..
2021Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Trac..
2021Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
Volgende evenement op ACHILLES THERAPEUTICS PLC